$3500 | Single User
$7000 | Site License
$10500 | Enterprise License

Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Pipeline Review, H2 2018 [Report Updated: 16-10-2018]

Published by Global Markets Direct: 16 Oct 2018 | 224283 | In Stock

Introduction

Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Pipeline Review, H2 2018

Summary

Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Carbonic anhydrase 9 (CA9/CAIX) is an enzyme encoded by the CA9 gene. CA IX is a transmembrane protein and is one of only two tumor-associated carbonic anhydrase isoenzymes. It is expressed in all clear-cell renal cell carcinoma, but is not detected in normal kidney or most other normal tissues. It participate in a variety of biological processes, including respiration, calcification, acid-base balance, bone resorption, and the formation of aqueous humor, cerebrospinal fluid, saliva, and gastric acid.

Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) pipeline Target constitutes close to 11 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively. Report covers products from therapy areas Oncology and Central Nervous System which include indications Breast Cancer, Endometrial Cancer, Glioblastoma Multiforme (GBM), Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Peripheral Neuropathy (Sensory Neuropathy), Prostate Cancer, Recurrent Glioblastoma Multiforme (GBM), Small-Cell Lung Cancer and Solid Tumor.

The latest report Carbonic Anhydrase 9 - Pipeline Review, H2 2018, outlays comprehensive information on the Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1)

- The report reviews Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) targeted therapeutics and enlists all their major and minor projects

- The report assesses Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents
for Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Pipeline Review, H2 2018 [Report Updated: 16-10-2018]

  • Table of Contents

    List of Tables

    List of Figures

    Introduction

    Global Markets Direct Report Coverage

    Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Overview

    Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Therapeutics Development

    Products under Development by Stage of Development

    Products under Development by Therapy Area

    Products under Development by Indication

    Products under Development by Companies

    Products under Development by Universities/Institutes

    Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Therapeutics Assessment

    Assessment by Mechanism of Action

    Assessment by Route of Administration

    Assessment by Molecule Type

    Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Companies Involved in Therapeutics Development

    Akshaya Bio Inc

    DualTpharma BV

    EstryX Pharma Ltd

    Kalgene Pharmaceuticals Inc

    SignalChem Lifesciences Corp

    Telix Pharmaceuticals Ltd

    Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Drug Profiles

    (acetazolamide + temozolomide) - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    DTP-348 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    ESE-15-ol - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    SLC-0111 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    SLC-149 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecules to Inhibit Carbonic Anhydrase IX for Oncology - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecules to Inhibit Carbonic Anhydrase IX for Oncology - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecules to Inhibit Carbonic Anhydrases and MMPs for Metastatic Melanoma - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    STX-140 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    TX-250 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Vaccine to Target CA9 for Oncology - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Dormant Products

    Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Product Development Milestones

    Featured News & Press Releases

    Aug 23, 2018: Heidelberg Pharma: Partner Telix Pharmaceuticals Files Phase III Trial for Kidney Cancer Imaging in Europe

    Jul 26, 2018: Telix Pharmaceuticals and JFE Progress japanese manufacturing partnership

    Jun 25, 2018: Telix and Isologic conclude manufacturing agreement for North America

    May 02, 2018: Telix Pharmaceuticals Selects Goodwin Biotechnology as Manufacturing Scale-up Partner

    May 02, 2018: Telix Pharmaceuticals Selects Goodwin Biotechnology as Manufacturing Scale-up Partner

    Jan 30, 2018: Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

    Dec 04, 2014: SignalChem Initiates Phase 1 Clinical Trial for SLC-0111 in Solid Tumours

    Appendix

    Methodology

    Coverage

    Secondary Research

    Primary Research

    Expert Panel Validation

    Contact Us

    Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

224283 | GMDHC1729TDB

Number of Pages

48

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Pipeline Review, H1 2018
Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Ce...
17 Apr 2018 by Global Markets Direct USD $3,500 More Info
Carbonic Anhydrase Inhibitor -Pipeline Insight, 2018
“Carbonic Anhydrase Inhibitor - Pipeline Insight, 2018” report by DelveInsight offers comprehensive ...
14 Feb 2018 by Delve Insight USD $1,250 More Info
Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Pipeline Review, H2 2017
Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Ce...
10 Oct 2017 by Global Markets Direct USD $3,500 More Info
Carbonic Anhydrase Inhibitor -Pipeline Insights, 2017
DelveInsight’s, “Carbonic Anhydrase Inhibitor-Mechanism of action Insights, 2017”, report provides c...
01 Sep 2017 by Delve Insight USD $1,250 More Info
Carbonic Anhydrase 1 (CA1) Inhibitors -Pipeline Insights, 2017
DelveInsight’s, “Carbonic Anhydrase 1 (CA1) Inhibitors-Pipeline Insights, 2017”, report provides in ...
30 May 2017 by Delve Insight USD $1,250 More Info
Carbonic Anhydrase 2 (CA2) Inhibitors -Pipeline Insights, 2017
DelveInsight’s, “Carbonic Anhydrase 2 (CA2) Inhibitors-Pipeline Insights, 2017”, report provides in ...
30 May 2017 by Delve Insight USD $1,250 More Info
Carbonic Anhydrase Inhibitors -Pipeline Insights, 2017
DelveInsight’s, “Carbonic Anhydrase Inhibitors-Pipeline Insights, 2017”, report provides in depth in...
30 May 2017 by Delve Insight USD $1,250 More Info
Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Pipeline Review, H2 2016
Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Ce...
26 Oct 2016 by Global Markets Direct USD $3,500 More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Pipeline Review, H2 2018 [Report Updated: 16-10-2018] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data